 At the end of each treatment period, fasting blood will be taken to measure glycaemic response HbA1c, fasting glucose and insulin concentrations trough drug levels and to confirm continued eligibility. Weight, blood pressure and. data about patient experience will also be collected including perceived side effects, preparedness to remain on therapy, psychological health and health related quality of life. 